MedTrace Logo

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

NCT04085900 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40000

Last updated 2023-07-13

No results posted yet for this study

Summary

All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually.

All subjects will also be followed by record linkage to Cancer Register and Population Register.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

Blood and saliva

Collect blood and saliva samples from participants

DIAGNOSTIC_TEST

P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA

Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.

DIAGNOSTIC_TEST

Fiberoptic endoscopy and biopsy

Screening participants will refer to fiberoptic endoscopy and biospy

Sponsors & Collaborators

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Xiamen University

    collaborator OTHER

  • Zhongshan People's Hospital, Guangdong, China

    lead OTHER

Principal Investigators

  • Mingfang Ji, MD · Zhongshan People's Hospital, Guangdong, China

Eligibility

Min Age
30 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2024-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04085900 on ClinicalTrials.gov